Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS

Clinical Immunology

Volumn 109, Issue 1, 2003, Pages 89-102

  Leone, Giuseppe ^a   Voso, Maria Teresa ^a   Teofili, Luciana ^a   Lübbert, Michael ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

5 Azacytidine; Decitabine; Demethylation; Histone acetylation; Transcription modulation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID DERIVATIVE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG MEGADOSE; FATIGUE; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; INJECTION SITE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 0142216208     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6616(03)00207-9     Document Type: Article

References (117)

1. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
2. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:2000;168-174.
3. Issa J.P., Baylin S.B., Herman J.G. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 11:(Suppl. 1):1997;7-11.
4. Eden A., Gaudet F., Waghmare A., Jaenisch F. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 300:2003;455.
5. Gaudet F., Hodgson J.G., Eden A., Jackson L., Dausman J., Gray J.W., Leonhardt H. Jaenisch, Induction of tumors in mice by genomic hypomethylation. Science. 300:2003;489-492.
6. Saavedra H.I., Wang T.H., Hoyt P.R., Popp D., Yang W.K., Stambrook P.J. Interleukin-3 increases the incidence of 5-azacytidine-induced thymic lymphomas in pBOR-II-3 mice. Cell. Immunol. 10:1996;116-123.
7. Melki J.R., Vincent P.C., Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59:1999;3730-3740.
8. Rush L.J., Dai Z., Smiraglia D.J., Gao X., Wright F.A., Fruhwald F., et al. Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood. 97:2001;3226-3233.
9. Li Q., Kopecky K.J., Mohan A., Willman C.V., Appelbaum F.R., Weick J.K., Issa J.P.J. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin. Cancer Res. 5:1999;1077-1084.
10. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., Issa J.P.J. Methylation profiling in acute myeloid leukemia. Blood. 97:2001;2823-2829.
11. Rush L.J., Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett. 185:2002;1-12.
12. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/DK4. Nature. 366:1993;704-707.
13. Teofili L., Morosetti R., Martini M., Urbano R., Putzulu R., Rutella S., et al. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp. Hematol. 28:2000;519-526.
14. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
15. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
16. Hebert J., Cayuela J.M., Berkeley J., Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T but not from B-cell lineage acute lymphoblastic leukemias. Blood. 84:1994;4038-4044.
17. Ogawa S., Hangaishi A., Miyawaki S., Hirosawa S., Miura Y., Takeyama K., et al. Loss of cyclin-dependent kinase 4-inhibitor (p16; MTS 1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood. 86:1995;1548-1556.
18. Hirama T., Koeffler H.P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 86:1995;841-854.
19. Uchida T., Kinoshita T., Saito H., Hotta T. CDKN2 (MTS1/p16INK4A) gene alternations in hematological malignancies. Leuk. Lymphoma. 24:1997;449-461.
20. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 91:1998;2985-2990.
21. Uchida T., Kinoshita T., Nagai H., Nakahara Y., Saito H., Hotta T., Murate T. Hypermethylation of the p15/INK4B gene in myelodysplastic syndromes. Blood. 4:1997;1403-1409.
22. Tien H.F., Tang Tsay W., Liu M.C., Lee F.Y., Wang C.H., Chen Y.C., Shen M.C. Methylation of the p15INK4B gene in myelodysplastic syndrome, it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 112:2001;148-154.
23. M. Lubbert, Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes, Leukemia 2003. In press.
24. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D., et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 88:1996;4296-4303.
25. Das-Gupta E.P., Seedhouse C.H., Russell N.H. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br. J. Haematol. 14:2001;307-312.
26. Zhu Y.M., Das-Gupta E.P., Russel N.H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood. 94:1999;733-740.
27. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 99:2002;1909-1912.
28. Casorelli I., Offman J., Mele L., Pagano L., Sica S., D'Errico M., Giannini G., Leone G., Bignami M., Karran P. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair. 2:2003;547-559.
29. Seedhouse C.H., Das-Gupta E.P., Russell N.H. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia. 17:2003;83-88.
30. Au W.Y., Fung A., Man C., Ma S.K., Wan T.S., Liang R., Kwong Y.L. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br. J. Haematol. 120:2003;1062-1065.
31. Herman J.G., Jen J., Merlo A., Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56:1996;722-727.
32. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 7:1997;837-841.
33. Mizuno S.I., Chijiwam T., Okamura T., Akashi K., Fukumaki Y., Niho Y., Sasaki H. Expression of DNAmethyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 97:2001;1172-1179.
34. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., Groffen J., Heisterkamp N., Nichols P.W., et al. Quantitative measure of c-abl & p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 95:2000;2990-2992.
35. Zion M., Ben-Yehuda D., Avrahamm A., Cohenm O., Wetzler M., Melloul D., Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA. 91:1994;10722-10726.
36. Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 94:1999;2452-2460.
37. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., Groffen J., Heisterkamp N., Nichols P.W., et al. Quantitative measure of c-abl. & p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 95:2000;2990-2992.
38. Hernandez-Boluda J.C., Cervantes F., Colomer D., Vela M.C., Costa D., Paz M.F., Esteller M., Montserrat E. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp. Hematol. 31:2003;204-210.
39. Aviram A., Witenberg B., Shaklai M., Blickstein D. Detection of methylated ABL1 promoter in Philadelphia-negative myeloproliferative disorders. Blood Cells Mol. Dis. 30:2003;100-106.
40. Yang M.Y., Liu T.C., Chang J.C., Lin P.M., Lin S.F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 101:2003;3205-3211.
41. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 295:2002;1079-1082.
42. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:1998;815-818.
43. Chim C.S., Liang R., Tam C.Y., Kwong Y.L. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J. Clin. Oncol. 19:2001;2033-2040.
44. Teofili L., Martini M., Luongo M., Diverio D., Capelli G., Breccia M., Lo Coco F., Leone G., Larocca L.M. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia. 17:2003;919-924.
45. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantarjian H.M., Issa J.P. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8:2002;2217-2224.
46. G. Garcia-Manero, S. Jeha, J. Daniel, J. Williamson, M. Albitar, H.M. Kantarjian, J.P. Issa, Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia, (2003) 695-702.
47. Hofmann W.K., Tsukasaki K., Takeuchi N., Takeuchi S., Koeffler H.P. Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma. Leuk. Lymphoma. 42:2001;1107-1109.
48. ink4b genes as a marker of disease in the follow-up of non-Hodgkin's lymphomas. Br. J. Haemato. 109:2000;97-101.
49. Garcia M.J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas. Am. J. Pathol. 161:2002;1007-1013.
50. Child F.J., Scarisbrick J.J., Calonje E., Orchard G., Russell-Jones R., Whittaker S.J. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J. Invest. Dermatol. 118:2002;941-948.
51. Kim Y.S., Kim J.S., Jung H.C., Lee C.H., Kim C.W., Song I.S., Kim C.Y. Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. J. Gastroenterol. 37:2002;17-22.
52. Nakamura M., Sakaki T., Hashimoto H., Nakase H., Ishida E., Shimada K., Konishil N. Frequent alterations of the p14ARF and p16INK4a genes in primary central nervous system lymphomas. Cancer Res. 61:2000;6335-6339.
53. Lindstrom M.S., Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin, Cancer Biol. 12:2002;381-387.
54. Katzenellenbogen R.A., Baylin S.B., Herman J.G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 93:1999;4347-4353.
55. Kramer A., Schultheis B., Bergmann J., Willer A., Hegenbart U., Ho A.D., Goldschmidt H., Hehlmann R. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia. 16:2002;1844-1851.
56. Sanz R., Lopez-Perez R., Moro M.J., Ocio E., Hernandez J., Megido M., Caballero M.D., Fernandez-Calvo J., Barez A., Almeida J., Orfao A., Gonzalez M., San Miguel J.F. Methylation is an inactivating Mateos MV Mateos MV, Garcia-mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br. J. Haematol. 118:2002;1034-1040.
57. Li Y., Nagai H., Ohno T., Yuge M., Hatano S., Ito E., Mori N., Saito H., Kinoshita T. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 100:2002;2572-2577.
58. Shen L., Toyota M., Kondo Y., Obata T., Daniel S., Pierce S., Imai K., Kantarjian H.M., Issa J.P.J., Garcia-Manero G. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 101:2003;4131-4136.
59. Esteller M., Gaidano G., Goodman S.N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S.B., Herman J.G. Methylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl. Cancer Inst. 94:2002;26-32.
60. Mertens D., Wolf S., Schroeter P., Schaffner C., Dohner H., Stilgenbauer S., Lichter P. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood. 99:2002;4116-4121.
61. Fulop Z., Csernus B., Timar B., Szepesi A., Matolcsy A. Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia. Leukemia. 17:2003;411-415.
62. Bender C.M., Zingg J.M., Jones P.A. DNA methylation as a target for drug design. Pharm. Res. 15:1998;175-187.
63. Momparler L., Cotè S., Eliopoulos N. Pharmacologica approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for therapy of leukemia. Leukemia. 11:(Suppl. 1):1997;1-6.
64. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.P., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA. 95:1998;6870-6875.
65. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′ deoxycytidine treatment. Blood. 100:2002;2957-2964.
66. Teofili L., Martini M., Di Mario A., Rutella S., Urbano R., Luongo M., et al. Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood. 98:2001;495-497.
67. Wijermans P., Lübbert M., Verhoef G. DNA demethylating therapy in MDS: the effect of decitabine on the platelet count. Blood. 94:(Suppl. 1):1999;306a.
68. Cameron E.E., Bachman K.E., Myöhänen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107.
69. Shaker S., Bernstein M., Momparler L.F., Momparler R.L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res. 27:2003;437-444.
70. Trinh B.N., Long T.I., Nickel A.E., Shibata D., Laird P.W. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell. Biol. 22:2002;2906-2917.
71. Lübbert M., Wijermans P., Kunzmann R., Verhoef G., Bosly A., Ravoet C., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114:2001;349-357.
72. Creusot F., Acs G., Christman J.K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 57:1982;2041-2048.
73. Wilhelm M., O'Brien S., Rios M.B., Estey E., Keating M.J., Plunkett W., et al. Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk. Lymphoma. 34:1999;511.
74. Sorm F., Vesely J. The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice. Neoplasma. 11:1964;123.
75. Pliml J., Sorm F. Synthesis of 2′deoxy-D-ribofuranosyl-5- azacytosine. Collect. Czech. Chem. Commun. 29:1964;2060.
76. Taylor S.M., Jones P.A. Change in phenotypic expression in embryonic and adult cells treated with azacytidine. J. Cell. Physiol. 111:1982;187.
77. Christman J.K., Mendelsohn N., Herzog D., Scneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cell (HL-60). Cancer Res. 43:1983;763-769.
78. Momparler R.L. Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol. Ther. 30:1985;287-299.
79. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O.A., Di Fiore P.P. 5-Aza-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 64:1984;922-992.
80. Jutterman R., Li E., Jaenisch R. Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA. 91:1994;11797-11801.
81. Bestor T.H., Verdine G.L. DNA methyltransferase. Curr. Opin. Cell Biol. 6:1994;380-389.
82. Szyf M. Towards a pharmacology of DNA methylation. Trends Pharmacol, Sci. 22:2001;350-354.
83. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Genet. 24:2000;88-91.
84. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet. 25:2000;269-277.
85. Attadia V. Effects of 5-aza-2′-doxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. Leukemia. 7:(Suppl. 1):1993;9-16.
86. Leone G., Teofili L., Voso M.T., Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 87:2002;1324-1341.
87. Silverman L.R., Holland J.F., Weinberg R.S., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 7:(Suppl.1):1993;21-29.
88. Silverman L.R., Holland J.F., Demakos E.P., et al. Azacytidine (azaC) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 (abstract). Ann. Hematol. 68:(Suppl. 1):1994;12a.
89. Chitambar C.R., Libnoch J.A., Matthaeus W.G., Ash R.C., Ritch P.S., Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am. J. Hematol. 37:1991;100-104.
90. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2002;2429-2440.
91. Kornblith A.B., Herndon J.E., Silverman Lewis R., Demakos Erin P., Odchimar-Reissig R., Holland J., et al. Impact of Azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin. Oncol. 20:2002;2441-2452.
92. Zagonel V., Lo Re G., Marotta G., Babare R., Sardeo G., Gattei V., et al. 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 7:(Suppl. 1):1993;30-35.
93. Petti M.C., Mandelli F., Zagonel V., De Gregoris C., Merola M.C., Latagliata R., et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients, preliminary results. Leukemia. 7:(Suppl. 1):1993;36-41.
94. A. Pinto, V. Zagonel, V. Attadia, Bullian, V. Gattei, Carbone, et al. 5-Aza-2′-deoxycytidine as differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly, Bone Marrow Transplant. (1989) 4 (Suppl. 3) (1989) 28-32.
95. Wijermans P.W., Krulder J.W., Huijgens P.C., Neve P. Continuous infusion of low-dose 5-aza-2′- deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 11:1997;1-5.
96. Wijermans P., Lübbert M., Verhoef G., Bosly A., Ravoet C., Andre M., Ferrant A. Low-dose 5- aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956-962.
97. Tuzuner N., Coxm C., Rowe J.M., Watrous D., Bennett J.M. Hypocellular myelodysplastic syndromes (MDS), new proposals. Br. J. Haematol. 91:1995;612-617.
98. Wijermans P., Lübbert M., Verhoef G. Low dose Decitabine for elderly high risk MDS patients: who will respond? Blood. 100:(Suppl. 1):2002;355.
99. Lübbert M., Wijermans P.W., Engelhardt M., Otto F. Acute myeloid leukemia of the elderly and frail: hematologic and cytogenetic remission attained following repeated courses of low-dose Decitabine and outpatient management. Blood. 100:(Suppl. 1):2002.
100. Issa J.P., Garcia-Manero G., Mannari R., Thomas D., Giles F., Cortes J., et al. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies (abstract). Blood. 98:(Suppl. 1):2001;249.
101. Sacchi S., Kantarjian H.M., O'Brien S., Cortes J., Rios M.B., Giles F.J., Beran M., Koller C.A., Keating M.J., Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 86:1999;2632-2641.
102. Willemze R., Suciu S., Archimbaud E., Muus P., Stryckmans P., Louwagie E.A., et al. A randomized phase II study on the effects of 5-aza-2′- deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia, an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia. 11:(Suppl. 1):1997;S24-S27.
103. Fernandes M.S., Schaan M.D., Moschen M., Gerhardt L.M., Di Leone L., et al. Decitabine (5-aza-2′-deoxycytidine, DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia, preliminary observations. Leukemia. 11:(Suppl. 1):1997;S28-S31.
104. Camacho L., Ryan H.J., Chanel S., Maslak P., Salomoni P., Jakubowski A., et al. Transcription modulation; a pilot study of sodium phenylbutyrate plus 5-azacytidine (abstract). Blood. 98:(Suppl. 1):2001;460a.
105. Miller C.B., Herman J.G., Baylin S.B., Galm O., Yerian J.A., Gore S.D. A phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies (abstract). Blood. 98:(Suppl. 1):2001;622a.
106. 1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia. 13:1999;1243-1253.
107. Gore S.D., Samid D., Weng L.J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. 3:1997;1755-1762.
108. Rosenfeld H., Roberts J. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in the cell culture by glutaminase-asparaginase. Cancer Res. 41:1981;1324-1328.
109. Hudgins W.R., Shack S., Myers C.E., Samid D. Cytostatic activity of phenylacetate and derivatives against tumor cells: correlation with lipophilicity and inhibition of protein prenylation. Biochem. Pharmacol. 50:1995;1273-1279.
110. Yu K.H., Weng L.J., Fu S., Piantadosi S., Gore S.D. Augmentation of phenylbutyrate, induced differentiation of myeloid leukemia cells using all-trans retinoic acid. Leukemia. 13:1999;1258-1265.
111. Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman M., Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RAR underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 91:1998;2634-2642.
112. Breitman T.R., He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res. 60:1990;6268-6273.
113. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 94:1999;417-428.
114. Zhu W.G., Lakshmanan R.R., Beal M.D., Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61:2001;1327-1333.
115. Hassan H.T., Veit A., Maurer H.R. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays. J. Cancer Res. Clin. Oncol. 117:1991;227-231.
116. Gore S.D., Weng L.J., Zhai S., Figg W.D., Donehower R.C., Dover G.J., et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7:2001;2330-2339.
117. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.S., Dahmoush L., Kingma D.M., Turner M.L., Altemus R., Bates S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 98:2001;2865-2868.